Medicaid prescription limits: policy trends and comparative impact on utilization

BMC Health Services Research

Volumn 16, Issue 1, 2016, Pages

  Lieberman, Daniel A ^a   Polinski, Jennifer M ^b   Choudhry, Niteesh K ^c   Avorn, Jerry ^c   Fischer, Michael A ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CVS Caremark   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Health policy; Health services research; Medicaid; Pharmacoepimiology; Pharmacy benefits; Prescription drugs

Indexed keywords

GENERIC DRUG; PRESCRIPTION DRUG;

DRUG COST; DRUG UTILIZATION REVIEW; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE POLICY; HUMAN; MEDICAID; PRESCRIPTION; TRENDS; UNITED STATES;

DRUG COSTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; DRUGS, GENERIC; HEALTH POLICY; HUMANS; INTERRUPTED TIME SERIES ANALYSIS; MEDICAID; PRESCRIPTION DRUGS; UNITED STATES;

EID: 84954521243     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-016-1258-0     Document Type: Article

References (47)

1. The Kaiser Family Foundation's State Health Facts. Medicaid & CHIP. http://kff.org/state-category/medicaid-chip/ Accessed Jan 10, 2015.
2. Smith V, Gifford K, Ellis E, Rudowitz R, Snyder L. Moving Ahead Amid Fiscal Challenges: A Look at Medicaid Spending, Coverage and Policy Trends Results from a 50-State Medicaid Budget Survey for State Fiscal Years 2011 and 2012. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2011.
3. Smith V, Gifford K, Nardone M, Rudowitz R, Snyder L. A Mid-Year State Medicaid Budget Update for FY 2012 & A Look Forward to FY 2013. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2012.
4. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. N Engl J Med. 1987;317(9):550-6.
5. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin TJ, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325(15):1072-7.
6. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650-5.
7. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-9.
8. Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev. 2008;1:CD007017.
9. The Kaiser Family Foundation's State Health Facts. Medicaid Benefits: Prescription Drugs. [ http://kff.org/medicaid/state-indicator/prescription-drugs/ ] Accessed January 10, 2015.
10. National Pharmaceutical Council. Pharmaceutical Benefits Under State Medical Assistance Programs, 2001-2005, 2007. Reston, VA: 2000, 2001, 2002, 2003, 2004, 2005 & 2007.
11. Medicaid Drug Rebate Program Data. Baltimore, MD: Center for Medicare and Medicaid Services; 2001-2009.
12. First DataBank, National Drug Data File. San Francisco, CA: Hearst Corporation; 2011.
13. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4):421-9.
14. WHO Model List of Essential Medicines. 17 edition. Geneva, Switzerland: World Health Organization; 2012.
15. De Smet BD, Fendrick AM, Stevenson JG, Bernstein SJ. Over and under-utilization of cyclooxygenase-2 selective inhibitors by primary care physicians and specialists: the tortoise and the hare revisited. J Gen Intern Med. 2006;21(7):694-7.
16. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16(9):e228-234. e228-234.
17. Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010;303(14):1401-9.
18. Paul IM, Maselli JH, Hersh AL, Boushey HA, Nielson DW, Cabana MD. Antibiotic prescribing during pediatric ambulatory care visits for asthma. Pediatrics. 2011;127(6):1014-21.
19. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 32 edition. Silver Spring, MD: U.S. Food and Drug Administration; 2012.
20. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351(21):2187-94.
21. Fischer MA, Choudhry NK, Winkelmayer WC. Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing? Health Aff (Millwood). 2007;26(3):800-7.
22. Stolwijk AM, Straatman H, Zielhuis GA. Studying seasonality by using sine and cosine functions in regression analysis. J Epidemiol Community Health. 1999;53(4):235-8.
23. Polinski JM, Shrank WH, Huskamp HA, Glynn RJ, Liberman JN, Schneeweiss S. Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap. PLoS Med. 2011;8(8):e1001075-5.
24. Bruen B, Ghosh A. Medicaid Prescription Drug Spending and Use. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2004.
25. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282(24):2340-6.
26. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450-6.
27. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177-86.
28. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-41.
29. Schiller JS, Lucas JW, Ward BW, Peregoy JA. Summary health statistics for U.S. adults: National Health Interview Survey. Vital Health Stat 10. 2010;2012(252):1-207.
30. Newby LK, LaPointe NMA, Chen AY, Kramer JM, Hammill BG, DeLong ER, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203-12.
31. Garner JB. Problems of nonadherence in cardiology and proposals to improve outcomes. Am J Cardiol. 2010;105(10):1495-501.
32. Shrank WH, Choudhry NK, Liberman JN, Brennan TA. The use of generic drugs in prevention of chronic disease is far more cost-effective than thought, and may save money. Health Aff (Millwood). 2011;30(7):1351-7.
33. Casalino LP, Nicholson S, Gans DN, Hammons T, Morra D, Karrison T, et al. What does it cost physician practices to interact with health insurance plans? Health Aff (Millwood). 2009;28(4):w533-43.
34. Hsu J, Price M, Huang J, Brand R, Fung V, Hui R, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354(22):2349-59.
35. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA. 2004;291(15):1850-6.
36. Choudhry NK, Levin R, Avorn J. The economic consequences of non-evidence-based clopidogrel use. American Heart Journal. 2008;155(5):904-9.
37. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med. 2012;125(3):302. e301-307-302.e301-307.
38. Martin BC, McMillan JA. The impact of implementing a more restrictive prescription limit on Medicaid recipients. Effects on cost, therapy, and out-of-pocket expenditures. Med Care. 1996;34(7):686-701.
39. Greenland S, Morgenstern H. Ecological bias, confounding, and effect modification. Int J Epidemiol. 1989;18(1):269-74.
40. Choudhry NK, Shrank WH. Four-dollar generics - increased accessibility, impaired quality assurance. N Engl J Med. 2010;363(20):1885-7.
41. Sada MJ, French WJ, Carlisle DM, Chandra NC, Gore JM, Rogers WJ. Influence of payor on use of invasive cardiac procedures and patient outcome after myocardial infarction in the United States. Participants in the National Registry of Myocardial Infarction. J Am Coll Cardiol. 1998;31(7):1474-80.
42. The Medicaid Access Study Group. Access of Medicaid recipients to outpatient care. N Engl J Med. 1994;330(20):1426-30.
43. Asplin BR, Rhodes KV, Levy H, Lurie N, Crain AL, Carlin BP, et al. Insurance status and access to urgent ambulatory care follow-up appointments. JAMA. 2005;294(10):1248-54.
44. Smith V, Gifford K, Ellis E, Rudowitz R, Watts MO, Marks C. The Crunch Continues: Medicaid Spending, Coverage and Policy in the Midst of a Recession. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2009.
45. Library of Congress, Bill Summary & Status - 111th Congress (2009-2010) - H.R.3590 - CRS Summary [ http://thomas.loc.gov/cgi-bin/bdquery/z?d111:H.R.3590: ]. Accessed January 10, 2015.
46. Holahan J, Headen I. Report and Briefing on Medicaid Coverage and Spending in Health Reform: National and State-By-State Results for Low-Income Adults. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2010.
47. Musumeci M. A Guide to the Supreme Court's Affordable Care Act Decision. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2012.